These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12216526)

  • 1. Antiretroviral therapy 2002.
    Zambrano CH
    Posit Aware; 2002; 13(1):27. PubMed ID: 12216526
    [No Abstract]   [Full Text] [Related]  

  • 2. In for the long haul: debate paves way for long-term trials.
    Bass E
    Res Initiat Treat Action; 2001; 7(1):5-7. PubMed ID: 11548386
    [No Abstract]   [Full Text] [Related]  

  • 3. Guidelines for kidney transplantation in patients with HIV disease.
    Bhagani S; Sweny P; Brook G;
    HIV Med; 2006 Apr; 7(3):133-9. PubMed ID: 16494626
    [No Abstract]   [Full Text] [Related]  

  • 4. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 5. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiretroviral rounds. The when, why and how of switching.
    Henry K; Daar ES
    AIDS Clin Care; 2003 Jun; 15(6):58-9. PubMed ID: 12866482
    [No Abstract]   [Full Text] [Related]  

  • 7. The current status of antiretroviral therapy in Africa.
    Bray DH
    J HIV Ther; 2006 Mar; 11(1):7-10. PubMed ID: 16706249
    [No Abstract]   [Full Text] [Related]  

  • 8. How infrequent are opportunistic diseases and immune reconstitution syndromes among HIV-infected individuals who have favorable CD4+ cell count responses to antiretroviral therapy?
    Phillips P
    Clin Infect Dis; 2005 May; 40(9):1379-80; author reply 1380-1. PubMed ID: 15825049
    [No Abstract]   [Full Text] [Related]  

  • 9. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience.
    Rajasekaran S; Jeyaseelan L; Vijila S; Gomathi C; Raja K
    AIDS; 2007 Jul; 21 Suppl 4():S47-53. PubMed ID: 17620752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
    Rodés B; Toro C; Jiménez V; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult.
    Flanigan TP; Mitty JA
    Clin Infect Dis; 2006 Jun; 42(11):1636-8. PubMed ID: 16652322
    [No Abstract]   [Full Text] [Related]  

  • 13. [HIV infection: in the HAART era, CD4 makes the difference].
    Varsky C
    Acta Gastroenterol Latinoam; 2004; 34(3):117-9. PubMed ID: 15742925
    [No Abstract]   [Full Text] [Related]  

  • 14. Coinfection with HIV and hepatitis C virus and immune restoration during HAART.
    Manfredi R
    Clin Infect Dis; 2006 Jan; 42(2):298-9. PubMed ID: 16355345
    [No Abstract]   [Full Text] [Related]  

  • 15. CD4 cell count-guided treatment interruption: be smart and wait for more evidence.
    Arduino R
    Clin Infect Dis; 2005 Mar; 40(5):735-7. PubMed ID: 15714421
    [No Abstract]   [Full Text] [Related]  

  • 16. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge of and adherence to antiretroviral therapy.
    Parienti JJ
    Clin Infect Dis; 2003 Sep; 37(6):861-2; author reply 862-3. PubMed ID: 12955656
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.